

1 **Title:** The Global case-fatality rate of COVID-19 has been declining disproportionately  
2 between top vaccinated countries and the rest of the world

3

4 **Authors:** Najmul Haider<sup>1</sup>†, Mohammad Nayeem Hasan<sup>2</sup>†, Rumi A Khan<sup>3</sup>, David McCoy<sup>4</sup>, Francine  
5 Ntoumi<sup>5,6</sup>, Osman Dar<sup>7</sup>, Rashid Ansumana<sup>8</sup>, Md. Jamal Uddin<sup>2,\*</sup>, Alimuddin Zumla<sup>9,10</sup>, Richard A  
6 Kock<sup>1</sup>

7

8 **Affiliations:**

9 <sup>1</sup> The Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hatfield,  
10 Hertfordshire, United Kingdom

11 <sup>2</sup> Department of Statistics, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh.

12 <sup>3</sup> Department of Critical Care Medicine, Orlando Regional Medical Centre, Orlando, FL, USA

13 <sup>4</sup> Institute of Population Health Sciences, Barts and London Medical and Dental School, Queen Mary  
14 University of London, London, UK

15 <sup>5</sup> Congolese Foundation for Medical Research, Brazzaville, Republic of Congo.

16 <sup>6</sup> Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany

17 <sup>7</sup> Chatham House Centre for Global Health Security, Royal Institute of International Affairs, London,  
18 UK

19 <sup>8</sup> School of Community Health Science, Njala University, Bo Campus, Sierra Leone

20 <sup>9</sup> Division of Infection and Immunity, Centre for Clinical Microbiology, University College London,

21 <sup>10</sup> NIHR-BRC, University College London Hospitals, London, United Kingdom.

22

23 † These authors contributed equally

24

25 \*Corresponding author

26 Corresponding author address:  
27 Department of Statistics,  
28 Shahjalal University of Science and Technology,  
29 Sylhet 3114, Bangladesh.  
30 E-mail: [jamal-sta@sust.edu](mailto:jamal-sta@sust.edu)

31

32

### 33 **Abstract**

34 Globally 58.83% human population received at least one dose of the COVID-19 vaccines as of 5  
35 January 2021. COVID-19 vaccination rollout is progressing at varied rates globally and data on the  
36 impact of mass vaccination on infection and case-fatality rates require definition. We compared the  
37 global reported cumulative case-fatality rate (rCFR) between top-20 countries with COVID-19  
38 vaccination rates (>125 doses/100 people) and the rest of the world, before and after commencement  
39 of vaccination programmes.

40  
41 We considered the 28th day of receiving the first vaccine in the world as a cut-off to compare the pre-  
42 vaccine period (Jan 1, 2020 – Jan 5, 2021) and the post-vaccine period (Jan 6, 2021- Jan 5, 2022). We  
43 used a Generalized linear mixed model (GLMM) with a beta distribution to investigate the association  
44 between the CFR and potential predictors of each country and reported the relative risk (RR) of each  
45 variable.

46  
47 The mean rCFR of COVID-19 in the top-20 countries with vaccination rates was 1.83 (95% CI: 1.24-  
48 2.43) on 5 Jan 2021 and 1.18 (95% CI: 0.73-1.62) on 5 Jan 2022. The CFR for the rest of the world on  
49 5 Jan 2021 was 2.32 (95% CI: 1.86-2.79) and 2.20 (95% CI: 1.86-2.55) on 5 January 2022. In Sub-  
50 Saharan Africa, the CFR remained roughly unchanged at 1.97 (95% CI: 1.59-2.35) on 5 Jan 2021 and  
51 1.98 (95% CI:1.58-2.37) on 5 Jan 2022. The GLMM showed vaccination (/100 population) (RR:0.37)  
52 and Stringency Index (RR:0.88) were strong protective factors for the country's COVID-19 CFR  
53 indicating that both vaccination and lockdown measures help in the reduction of COVID-19 CFR.

54  
55 The rCFR of COVID-19 continues to decline, although at a disproportionate rate between top  
56 vaccinated countries and the rest of the world. Vaccine equity and faster roll-out across the world is  
57 critically important in reducing COVID-19 transmission and CFR.

58

59

60

61 **Key Questions:**

62 **What is already known:**

- 63 • Vaccination can reduce the case-fatality rate of COVID-19. Globally, the COVID-19  
64 vaccination rollout is progressing at varied rates.

65

66 **What are the new findings?**

- 67 • In the top-20 countries with vaccination, >200 doses of vaccines are given per 100 people on  
68 5<sup>th</sup> Jan 2022, In the rest of the world, the figure is 105, and in Sub-Saharan Africa (SSA) only  
69 15.72
- 70 • After the introduction of COVID-19 vaccination the reported case-fatality rate (rCFR) of  
71 COVID-19 has reduced by 35% in the top-20 countries with vaccination, 8% in the rest of the  
72 world roughly unchanged in SSA.
- 73 • The doses of COVID-19 vaccines (/100 people) and rCFR has a negative correlation on 5 Jan  
74 2022 ( $r=-0.296$ ,  $p<0.001$ ).
- 75 • The COVID-19 vaccination and Stringency Index are strong protective factors for the  
76 country's COVID-19 rCFR indicating that both vaccination and lockdown measures help in  
77 reduction of COVID-19 rCFR.

78

79 **What do the new findings imply:**

- 80 • The disproportionate case-fatality rate of COVID-19 between top vaccinated countries and  
81 the rest of the world demand fast and equitable vaccine rollout globally to reduce COVID-19  
82 transmission and CFR

83

84 **Keywords:** COVID-19, SARS-CoV-2, Case-fatality rate, Vaccine equity, Variants of Concern

85

86

87

88 **Introduction:**

89

90 In the early stages of the COVID-19 pandemic, the WHO-China Joint Mission on Coronavirus  
91 Diseases (COVID-19) 28 February 2020 report indicated a crude fatality ratio of 3.8% among the first  
92 55,924 laboratory-confirmed cases <sup>1</sup>. Subsequently, systematic reviews on the case-fatality rate (CFR)  
93 of COVID-19 reported an estimated CFR between 2.3-3.6% <sup>2-5</sup>. The global cumulative reported case  
94 fatality rate (rCFR) of COVID-19 has increased up until the 17<sup>th</sup> epidemiological week (April 22–28,  
95 2020) of detection of SARS-CoV-2 in Wuhan China at 7.2, and then started to decline steadily up  
96 until 31 December 2021 at 2.2 <sup>6</sup>. The decreasing rate of CFR has been explained by an increased rate  
97 of infection in the younger population or by the improvement of health care management, shielding  
98 from infection, and/or repurposing of several drugs that had shorted both hospitals stays and saved  
99 lives <sup>6</sup>. However, during the last quarter of the year, 2020 different variants of concern/Interest  
100 (VOC/VOI) of SARS-CoV-2 started to emerge with increased transmissibility <sup>7</sup>. Of them, Alpha (first  
101 detected in the UK in September 2020), Beta (first documented in South Africa in May 2020),  
102 Gamma (first detected in Brazil in November 2020), and Delta (first detected in India in October  
103 2020) all reported having higher infectivity and severity than the virus originally detected in Wuhan,  
104 China <sup>7,8</sup>. During November 2021, a new variant of concern, Omicron was reported to WHO (first  
105 reported from South Africa on 24 November 2021)<sup>9</sup>. Unlike previous VOC, Omicron shows a  
106 relatively lower case-fatality rate although the variant has a high transmissibility <sup>10,11</sup>.

107

108 Vaccination can reduce the case-fatality rate of COVID-19. Several vaccines have been approved for  
109 emergency use by the Food and Drug Administration, USA, the European Medicine Agency, and the  
110 Public Health England and the World Health Organization approved use of a few Vaccines across the  
111 world. The real-world data had shown the effectiveness of the vaccines in terms of preventing  
112 infection by 60-92%<sup>12,13</sup>, hospitalization by 87-94%<sup>12,14</sup> and deaths by 72%- 100%<sup>12,15</sup> after 7-28 days  
113 of receiving the second dose of the vaccines for Alpha, Beta, or Delta VOC.

114

115 Vaccines are not distributed equitably in the world. Although COVID-19 vaccines were developed at  
116 an unprecedented rate through the advancement of science and global cooperation, the distribution of  
117 the vaccine across the world is questionable <sup>16</sup>. Current global vaccination rates of roughly 6.7  
118 million doses per day translate to achieving herd immunity in approximately 4.6 years <sup>16</sup>. Vaccine  
119 distribution is absent or very negligible in many of the low-income countries, and experts anticipated  
120 that 80% of the population in low-income countries would not receive a vaccine at the end of 2021 <sup>16</sup>  
121 which has been the case.

122

123 As the world enters the 3<sup>rd</sup> year of the COVID-19 pandemic, globally, as of 13 January 2022, there  
124 have been over 315,3450, 967 confirmed cases of COVID-19, including 5,510,174 deaths, reported to  
125 WHO <sup>17</sup>. COVID-19 vaccination rollout globally has progressed at varying rates and data on the  
126 impact of mass vaccination on infection and case-fatality rates require definition. To this end, we  
127 compared the global rCFR between the top-20 countries with vaccination rates (minimum  
128 vaccination: 125 dose/100 people) and the rest of the world, before and after commencement of  
129 vaccination programs. We further quantified the impacts of vaccinations, other control measures, and  
130 relevant variables on Covid-19 CFR.

131

## 132 **Methods:**

### 133 **COVID-19 data**

134 The necessary COVID-19 related data, including daily new cases, daily new deaths, total deaths, and  
135 total deaths per million inhabitants, vaccination, were collected from the WHO daily COVID-19  
136 situation reports of 210 countries from January 01, 2020, to January 05, 2022 <sup>18</sup>. On 8<sup>th</sup> December  
137 2020, the first human in the world received an approved COVID-19 vaccine <sup>19</sup>. We considered  
138 the 28th day of receiving the first vaccine in the world as a cut-off to compare the pre-vaccine period  
139 (Jan 1, 2020 – Jan 5, 2021) and the post-vaccine period (Jan 6, 2021- Jan 5, 2022).

140

141

142 **Reported case-fatality rate (rCFR)**

143 We estimated daily cumulative rCFR COVID-19 (please read Hasan et al <sup>6</sup> for the definition of rCFR)  
144 as the number of deaths per 100 COVID-19 confirmed cases. In some instances, we aggregated the  
145 daily cases and deaths record by week. As the number of cases and deaths both are a fraction of total  
146 cases or deaths globally, we considered the term as reported CFR or to make a simplified version as  
147 rCFR <sup>6</sup> .

148

149 **Time series model to predict the trend**

150 Three forecasting models (i.e., auto-regressive integrated moving average (ARIMA), automatic time-  
151 series forecasting model which is also known as ‘Prophet model’, and simple exponential smoothing  
152 (SES)), to identify the global trend of COVID-19 rCFR. We also used the Mann-Kendall (M-K) trend  
153 analysis to identify the presence of any trend and the direction of the trend (increasing or decreasing).  
154 We developed a generalized linear mixed model (GLMM) with beta distribution to identify whether  
155 the explanatory variables have any relationship between the country’s rCFR of COVID-19. These  
156 methods supported us to make a credible conclusion on the trend of COVID-19 rCFR over the time.  
157 All analyses were carried out using the statistical software R version 3.5.2.2 <sup>20</sup> and SAS <sup>21</sup> .

158

159 We selected the SES, ARIMA, and Prophet Models because the key outcome variable (rCFR) is  
160 dependent on previous records (time-series events) and all these three models can take this into  
161 account. Using the time series models with the reported COVID-19 data, we forecasted trends for the  
162 prospective 10-days and visualized in the figure. SES is suggested as a good benchmark model to  
163 compare the performance of the ARIMA and Prophet models. We also used M-K trend analysis to  
164 identify the daily or weekly cumulative trend (increasing or decreasing) of COVID-19 rCFR <sup>22</sup> . The  
165 details of the SES, ARIMA, and Prophet models are discussed in an earlier article on COVID-19 <sup>6</sup> .

166

167 **Outcome and predictor variables**

168 We collected a selected number of predictors variables from the World Bank and other UN sources  
169 such as population density <sup>23</sup> , percentage of people above 65 years of age <sup>24</sup> , Gross Domestic Product

170 (GDP)<sup>25</sup>, worldwide governance indicators (WGI)<sup>26</sup>, and Global Health Security Index (GHSI)<sup>27</sup>, the  
171 prevalence of obesity<sup>28</sup> or from “Our World in Data”<sup>29</sup> in our analyses. We also included the  
172 country-specific prevalence of diabetes<sup>29</sup> and cardiovascular disease<sup>29</sup> to explain the variation of  
173 COVID-19 rCFR. The GHSI index scored between 0 and 100 to indicate the country’s capacity for  
174 early detection and reporting for epidemics<sup>27</sup>. The WGI scored between -2.5 and 2.5, where -2.5  
175 indicates the weakest and 2.5 indicates the strongest governance performance<sup>26</sup>. The Oxford  
176 COVID-19 Government Response Tracker systematically collects information from 148 countries on  
177 several policy responses that governments have taken, scores stringency of such measures, and  
178 aggregates them into a common Stringency Index (SI) in a daily basis<sup>30</sup>. In the Our World in Data<sup>29</sup>,  
179 the SI was calculated by using nine response indicators including school closures, workplace closures,  
180 and travel bans, rescaled to a value from 0 to 100 (100 = strictest)<sup>30</sup>. The value of the SI at any given  
181 day is the results of the mean of the nine indicators. Thus, the index reports a number that reflects the  
182 overall stringency of the government’s response. Higher index indicates a better overall response level  
183 <sup>30</sup>.

184

### 185 **Empirical evaluation**

186 We assessed the ARIMA and Prophet models by comparing their results to benchmarks model, the  
187 SES<sup>31</sup>. The SES also allows the most appropriate non-seasonal model for each series, allowing for  
188 any kind of error or trend component. We, then, analyse and compared the performance of the  
189 performance of the time series models with some of the commonly used measures to evaluate the  
190 prediction significance including coefficient of determination ( $R^2$ ), root mean square error (RMSE),  
191 and mean absolute error (MAE).

192

### 193 **Generalized Linear Mixed Models**

194 The Generalized Linear Mixed Models (GLMM) is an extension of the Generalized Linear Models  
195 (GLM) that allows the analysis of clustered categorical data, as in the case of repeated responses from  
196 different subjects<sup>32</sup>. One of the key advantages of GLMM is that it separates the levels of the models  
197 to account for the group effect nesting the lower-level observations. In this study, locations are treated

198 as the second level which group sequential observations within the same area, and independent  
199 variables are treated as repeated observations at the lower level. While the location data are assumed  
200 to be time-invariant, the independent data are assumed to be universal over the whole study area at a  
201 certain time point. The model describes a beta distribution family that has a logit link. We conducted  
202 GLMMs using the statistical software R<sup>33</sup>.

203

#### 204 **Statistical analysis**

205 We performed summary statistical of vaccine doses/100 inhabitant and rCFR by country in the top-20  
206 countries with vaccination rate, in SSA and in the rest of the world pre-and post-vaccination  
207 programme and reported the mean and inter-quantile range (IQR). We observed that the rCFR of  
208 COVID-19 has changed over time (**Fig. 1**). Using time-series models alone would not allow us to  
209 identify the reason behind the increasing and decreasing trend of COVID-19 rCFR. We explored  
210 whether the relationship between the rCFR of COVID-19 and country-level explanatory variables  
211 vary over time through generalized linear mixed models. As the trend of rCFR in both periods is  
212 different, we ran generalized linear mixed models to investigate the association between possible  
213 explanatory variables and tried to investigate which variables affect the most in both periods  
214 separately.

215

#### 216 **Patient and Public Involvement**

217 This study is based on different country's COVID-19 cases and deaths record reported to WHO. The  
218 study does not include any individual patient level data. The findings of the results will be helpful in  
219 the equitable distribution of COVID-19 vaccines. The authors acknowledge the authorities shared the  
220 COVID-19 cases and deaths record. Patients or members of the public were not involved in the  
221 design, conduct, reporting or dissemination plans of the research as it was neither appropriate to  
222 involve nor possible to include.

223

224

225



226 **RESULTS:**

227

228 More than 297.77 million cumulative confirmed cases and 5.47 million deaths had been documented  
 229 globally on 5 Jan 2022. More than 127.50 doses of COVID-19 vaccines are given per 100 population  
 230 globally as of 5 January 2022. For every 100 people, 201.11 doses of vaccines are given in the top-20  
 231 countries with COVID-19 vaccination rates, in the rest of the world, 105.20 doses of COVID-19  
 232 vaccines are given, whereas the number is just 15.72 in Sub-Saharan Africa (SSA) (**Table 1**). The  
 233 global reported CFR is estimated as 1.83 on 5<sup>th</sup> January 2021 which is has dropped by 35.5% at 1.18%  
 234 on 5<sup>th</sup> January 2022 in the top-vaccinated country. In the rest of the world the rCFR dropped from  
 235 2.32 on 5<sup>th</sup> January 2021 to 2.2 on 5<sup>th</sup> January 2022, reduced by only 8.4% only (**Table 1**). In the  
 236 SSA, the rCFR has increased by 0.5% over the period (1.97 vs. 1.98). The top five countries with  
 237 COVID-19 rCFR as of 5 Jan 2022 are Yemen (19.56%), Peru (8.75%), Mexico (7.44%), Sudan  
 238 (7.07%), and Ecuador (6.09%). The correlating coefficient between vaccination rate (/100 people) and  
 239 rCFR in different countries of the world on 5 Jan 2022 is estimated as -0.296 (p<0.001) (**Fig 2**).

240

241 **Table 1: The doses of COVID-19 vaccines and reported case-fatality rate (rCFR) of COVID-19**  
 242 **in the top-20 vaccinated countries and rest of the world during 5<sup>th</sup> Jan 2021 and 5<sup>th</sup> Jan 2022.**

	Top-20 countries with vaccination rates Mean (IQRs)	Rest of the world Mean (IQRs)	Global Mean (IQRs)	Sub-Saharan Africa Mean (IQRs)
Vaccination Doses/100 People (5 January 2022)	201.11 (190.38 – 211.84)	105.20 (91.28 – 119.11)	127.50 (113.56 – 141.44)	15.72 (35.31 – 26.12)
Reported CFR by 5 Jan 2021	1.83 (1.24 - 2.43)	2.32 (1.86 - 2.79)	2.26 (1.85 - 2.67)	1.97 (1.59 – 2.35)
Reported CFR by 5 January 2022	1.18 (0.73 – 1.62)	2.20 (1.86 – 2.55)	2.07 (1.76 - 2.39)	1.98 (1.58 – 2.37)
p-value (for differences of rCFR between 5 Jan 2021 and 5 Jan 2022)	0.001	0.340	0.069	0.972

243

244

245 **Factors associated with rCFR:**

246

247 In the GLMM, the estimated effect of each variable is presented in relative risk (RR) and its  
248 significance is shown by its p-value. The COVID-19 vaccination (0.37 [0.19–0.57]), GDP (0.75  
249 [0.64–0.87]), and stringency index (0.88 [0.86–0.89]) was negatively significantly associated with the  
250 COVID-19 rCFR indicating that vaccination, GDP and lockdown measures all contributed to  
251 reduction of rCFR of COVID-19. The percentage of people aged 65 years or above the age of the  
252 population of the country were significantly positively (RR: 1.17, 95% CI: 1.01–1.37) associated with  
253 COVID-19 rCFR (**Table 2**).

254

255 The table includes the various covariates and the random intercept in the model. The intraclass  
256 correlation coefficient (ICC) of 0.634 was calculated by dividing the variance of the random effect by  
257 the total variance. Thus, the spatial unit effects account for approximately 63.4% of the total variance  
258 of weekly rCFR, which suggests moderate reliability on location effects on weekly rCFR. It is also to  
259 be noted that with the introduction of a random intercept, “vaccination”, “population density”,  
260 “GDP”, “weeks” and “stringency index” had significant negative effects on weekly rCFR and “the  
261 percentage of people aged 65 and above” have significant positive effects.

262

263 **Table 2: Factors associated with reported Case-Fatality Rate (rCFR) of COVID-19 in different**  
264 **countries of the world using a generalized linear mixed model during 1<sup>st</sup> Jan 2020 and 5<sup>th</sup> Jan**  
265 **2022.**

266

Variables	Relative Risk [RR]	95% Confidence Interval	P-value
Vaccination	0.374	0.191 - 0.567	<0.001 ***
The percentage of people aged 65 and above	1.170	1.011 - 1.375	0.049*
Population density	0.895	0.798 - 1.002	0.048*
GDP	0.746	0.643 - 0.870	<0.001 ***
GHSI	1.123	0.955 - 1.321	0.150
WGI	1.050	0.906 - 1.213	0.500
Obesity (%)	1.121	0.993 - 1.269	0.060
Stringency index	0.882	0.864 - 0.887	<0.001 ***
Vaccination: Weeks	1.207	1.103 - 1.402	<0.001 ***
Weeks	0.914	0.817 - 0.955	0.015 **
Groups Name	Variance	Standard Deviation	
Location (Intercept)	0.3354	0.5791	
Weeks (Intercept)	0.0274	0.1655	
<b>Akaike information criterion (AIC)</b>	-201305.5	<b>Conditional <math>R^2</math></b>	0.710
<b>Bayesian Information Criterion (BIC)</b>	-201201.0	<b>Marginal <math>R^2</math></b>	0.207
<b>Root Mean Square Error (RMSE)</b>	0.021	<b>Intraclass correlation (ICC)</b>	0.634

267

### 268 **The Trend of global rCFR of COVID-19:**

269 In the ARIMA and Prophet Model, we found a strong declining trend of rCFR of COVID-19 between  
270 observed and predictive global rCFR of COVID-19 with an  $R^2$ , RMSE, and MAE value of 99.94%  
271 and 99.56%, 0.04 and 0.13, and 0.01 and 0.06, respectively (**Table 3**). In terms of accuracy, the  
272 ARIMA model performed better over Prophet and SES model (with better  $R^2$ , RMSE, and MAE  
273 value). The coefficient of determination of the ARIMA model was larger and errors are lower than  
274 Prophet and SES model. According to the forecast in both models, the ratio of COVID-19 rCFR is  
275 expected to decrease considerably in the coming 10 days (**Fig 1**). In M-K trend analysis, we found a  
276 negative trend of cumulative rCFR ( $p < 0.001$  and  $\tau = -0.79$ ). In Sen's slop test, the slope was -0.02  
277 (95% CI: -0.03 to -0.01).

278

279 **Table 3.** The summary of Simple Exponential Smoothing (SES), Auto-Regressive Integrated Moving  
280 Average (ARIMA), Automatic forecasting time-series model (Prophet), Mann-Kendall (M-K), trend  
281 and Sen's slope analysis. The SES, ARIMA, and Prophet models used daily cumulative reported case-  
282 fatality rate (rCFR) data whereas the M-K trend analysis and Sen's slop used weekly cumulative

283 rCFR data. The Kendall’s Tau value permits a comparison of the strength of correlation between two  
 284 data series (here, week of the year 2020 and rCFR) <sup>22</sup>.  
 285

Method & Period	$R^2$	RMSE	MAE
<b><i>Simple Exponential Smoothing</i></b>			
Overall	99.91%	0.04	0.01
<b><i>Auto-Regressive Integrated Moving Average</i></b>			
Overall ARIMA (4,1,3)	99.94%	0.04	0.01
<b><i>Automatic Forecasting time-series model</i></b>			
Overall	99.56%	0.13	0.06
<b><i>Mann-Kendell trend analysis</i></b>			
	<b>tau</b>	<b>P</b>	
	-0.79	<0.001	
<b><i>Sen’s slop test</i></b>			
	<b>Sen’s Slope</b>	<b>95% CI</b>	
	-0.02	-0.03 to -0.01	

286 *RMSE: Root Mean Square Error; MAE: Mean Absolute Error*

287

288

289 **Discussion:**

290

291 The global rCFR of COVID-19 has been declining since May 2020 and the rate become plateaued or  
 292 slightly increased with the emergence of different variants of concerns especially after the emergence  
 293 and spreading of Delta VOC of SARS-CoV-2 <sup>34</sup>. After the beginning of COVID-19 vaccines rollout,  
 294 the rCFR started to decline, although, at a different rate in top-20 countries with vaccination rates, and  
 295 the rest of the world. In SSA, where the vaccine rollout did not reach to a satisfactory mark yet, the  
 296 rCFR of COVID- 19 remained constant. Many factors affect the reduction of rCFR, however, our  
 297 analysis indicates that the combination of vaccination, lockdown measures (stringency index), and the  
 298 country’s GDP is contributing significantly to the reduction of rCFR. Earlier studies discussed

299 potential role of an increased rate of infection in younger people or by the improvement of health care  
300 management, shielding from infection, and/or repurposing of several drugs had a beneficial effect on  
301 reducing the fatality rate of COVID-19. This analysis complements previous findings, however,  
302 generating immediate impact of inequitable vaccine rollout globally, indicating the importance of  
303 equitable distribution of COVID-19 vaccine to reduce fatalities due to COVID-19.

304

305 The negative correlation between doses of COVID-19 vaccines given and rCFR indicates the  
306 effectiveness of vaccines in reducing COVID-19 related deaths globally. The vaccines thus provide a  
307 pathway out of this pandemic, but strong, innovative policies that ensure fast and equitable  
308 distribution are absent <sup>16</sup>. Vaccinating the world serves global interests of protecting each other's  
309 health, and economy <sup>16</sup>. Unless the vaccine reaches to a level of global herd immunity, these goals  
310 will not be accomplished <sup>16</sup>. Our analysis showed a great difference of vaccine roll out in top  
311 vaccinated counties (201 doses/100 people) and the low-income countries (e.g. 15 doses/100 people in  
312 SSA) on 5 Jan 2022 <sup>35</sup>. In high-income countries, third or even fourth dose of the COVID-19 vaccine  
313 programmes are ongoing <sup>36</sup> whereas more than 80% of people in the SSA did not receive a single dose  
314 of vaccine yet (as of 5 Jan 2022). The high-income countries organization (G7) nations have  
315 committed support for global vaccine procurement through the Covid-19 Vaccines Global Access  
316 (COVAX) program, which supplies vaccines to low-and-middle-income countries. Currently,  
317 COVAX planned to vaccinate at least 30% of the population of 92 low-and -middle income countries  
318 by the end of 2022 <sup>37</sup>.

319

320 We found the COVID-19 vaccination, stringency index, and GDP as significantly associated with the  
321 reduction of rCFR of COVID-19. The major vaccines (mRNA, or adenovirus vectored) all are highly  
322 effective in reducing hospital admission and deaths <sup>35</sup>, even though some of the vaccines were not  
323 very effective in limiting the infection <sup>35</sup>. Thus, the vaccine rollout helped the high-income countries  
324 quickly reduce the burden of patients in hospitals thus limiting fatalities of COVID-19. However, in  
325 the rest of the world where vaccine rollout is still far from achieving herd immunity (70-80% of  
326 people receiving full doses of vaccines) the case-fatality rate has not declined significantly compared

327 to that of the top vaccinated countries. However, in many countries especially in SSA, the natural  
328 infection had reached in a state to limit the infection and reduce the overall burden of the pandemic <sup>38</sup>.  
329 In the Republic of Congo 66% of people in Brazzaville <sup>39</sup> in Malawi, 64.9% of blood donors <sup>40</sup> and in  
330 the Central African Republic, 74% of community residents had antibodies to SARS-CoV-2 <sup>41</sup>.  
331  
332 Lockdown measures indicated as Stringency index has been associated with reduction of CFR of  
333 COVID-19. The Stringency index is a composite measure based on indicators including school  
334 closure, workplace closure, travel bans, and use of mask, and other social distancing practices. This  
335 has been associated with shielding vulnerable people from infection and contributes to the reduction  
336 of COVID-19 related fatalities. While lockdown has been shown beneficial in reducing cases and  
337 fatalities of COVID-19 in high-income countries <sup>42</sup>, in Africa, lockdown has shown low or no benefit  
338 in terms of limiting transmissions <sup>43</sup>. The country's GDP is another indicator associated with the  
339 reduction of COVID-19 rCFR. This is believed that countries with higher national income deployed  
340 vaccines at a faster rate which reduce the local transmission and reduced rate of hospitalization thus  
341 allowing them to concentrate on the vulnerable population, all synergistically helping them reduce the  
342 fatalities of COVID-19. Earlier studies have also identified these variables as a risk factors/protective  
343 factors for mortality/fatality rate of COVID-19 <sup>6,44,45</sup>.  
344  
345 Equitable distribution of SARS-CoV-2 vaccines is crucial to ending the COVID-19 pandemic <sup>46</sup>. The  
346 circulation of the SARS-CoV-2 across the world among the large unvaccinated populations might  
347 allow the virus to reassort to become a new VOC. Furthermore, many animal species are susceptible  
348 to SARS-CoV-2 including Mink, Primates, rodents, cats, and dogs <sup>47</sup>. Earlier studies showed the link  
349 of animal species in the generation of VOC including dogs for Alpha variant <sup>48</sup> and rodents for  
350 Omicron variant <sup>49</sup>. Thus, this is important to reduce the circulation of SARS-CoV-2 in the human and  
351 animal populations to avoid further epidemics caused by new VOC. Equitable and faster vaccine  
352 rollout is the key to reducing the circulation of SARS-CoV-2 across the world.  
353

354 **Limitation:**

355 The case, death record, and the number of people being tested are reported based on the number  
356 shared by countries of the world. However, different countries have different capabilities of testing  
357 populations, and countries used different strategies to test their population which has affected the  
358 reported cases and deaths figures. This ultimately affected our estimated CFR of COVID-19.  
359 However, this is a global issue, and we accept this limitation and thus refer to the CFR as reported  
360 CFR, not true Case-fatality rate. Also, this terminology should not be confused with the infection  
361 fatality rate. Although we found that vaccination and lockdown measures both are associated with the  
362 reduction of COVID-19 CFR, however, we could not differentiate the true impact of each measure  
363 separately although the RR of the vaccination is estimated as four times more effective compared to  
364 the lockdown measures.

365

366

367 **Conclusion:**

368 More than 201 doses of COVID-19 vaccines have been given per 100 people in the top-20 countries  
369 with higher vaccination rates, compared to 105 doses in the rest of the world and 16 doses in Sub-  
370 Saharan Africa as of 5<sup>th</sup> Jan 2022. Vaccination and reported CFR (rCFR) of COVID-19 has a negative  
371 correlation (-0.29) on 5 Jan 2022 indicating the effectiveness of the vaccines in reducing COVID-19  
372 related deaths. Globally, the reported CFR (rCFR) of COVID-19 has been declining since the  
373 beginning of the vaccination programme. However, the rCFR has dropped significantly in the top-20  
374 countries with vaccination rates (35%) compared to the rest of the world (8%), whereas it remained  
375 largely unchanged in Sub-Saharan Africa (1.97 on 5<sup>th</sup> Jan 2021 and 1.98 on 5<sup>th</sup> Jan 2022). The  
376 COVID-19 vaccination, lockdown measures, and country's GDP were associated with reduction of  
377 rCFR of COVID-19. Vaccine equity and faster roll-out across the world is critically important in  
378 reducing COVID-19 transmission and CFR.

379

380

381 **Contribution:** NH and RK originally planned the study, MNH collected the data, NH and MNH,  
382 MJU analyzed the data. NH prepared the first draft manuscript and MNH, RAK, DM, FN, OD, RA,  
383 MJU, AZ and RK reviewed the draft manuscripts. All authors approved the submission of the  
384 manuscript.

385

### 386 **Acknowledgements**

387 NH, FN, OD, RA AZ, RK are part of PANDORA-ID-NET Consortium (EDCTP Reg/Grant  
388 RIA2016E-1609) funded by the European and Developing Countries Clinical Trials Partnership  
389 (EDCTP2) programme, which is supported under Horizon 2020, the European Union's Framework  
390 Programme for Research and Innovation.

391

392 **Conflict of interest:** The authors declare that they have no conflict of interest

393

394 **Funding Source:** There was no funding for this research.

395

396 **Ethical approval:** This study does not include any individual-level data and thus does not require any  
397 ethical approval.

398

399 **Data sharing statement:** All the data presented in this manuscript are publicly available in “Our  
400 World in Data”, “WHO” or “United Nations” webpages. However, the corresponding author can be  
401 reached to specific queries on the data sources.

### 402 **References:**

- 403 1 WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).  
404 Geneva, Switzerland, 2020.
- 405 2 Ahammed T, Anjum A, Rahman MM, Haider N, Kock R, Uddin MJ. Estimation of novel  
406 coronavirus (COVID-19) reproduction number and case fatality rate: A systematic review and  
407 meta-analysis. *Heal Sci Reports* 2021; **4**: 1–11.
- 408 3 He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time,  
409 asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and  
410 sensitivity analysis. *J Med Virol* 2020; published online May. DOI:10.1002/jmv.26041.
- 411 4 Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease



- 412 Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel  
413 coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; **41**:  
414 145–51.
- 415 5 Fu L, Wang B, Yuan T, *et al.* Clinical characteristics of coronavirus disease 2019 (COVID-19)  
416 in China: A systematic review and meta-analysis. *J Infect* 2020; **80**: 656–65.
- 417 6 Hasan MN, Haider N, Stigler FL, *et al.* The Global Case-Fatality Rate of COVID-19 Has Been  
418 Declining Since May 2020. *Am J Trop Med Hyg* 2021; **104**: 2176–84.
- 419 7 Mahase E. Covid-19: How many variants are there, and what do we know about them?: Video  
420 1. *BMJ* 2021; **374**: n1971.
- 421 8 Mahase E. Covid-19: Death rate is 0.66% and increases with age, study estimates. *BMJ*. 2020.  
422 DOI:10.1136/bmj.m1327.
- 423 9 Petersen E, Ntoumi F, Hui DS, *et al.* Emergence of new SARS-CoV-2 Variant of Concern  
424 Omicron (B.1.1.529) - highlights Africa’s research capabilities, but exposes major knowledge  
425 gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and  
426 control efforts. *Int J Infect Dis* 2022; **114**: 268–72.
- 427 10 UK Health Security Agency. SARS-CoV-2 variants of concern and variants under  
428 investigation in England- Technical briefing: Update on hospitalisation and vaccine  
429 effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). London, 2021.
- 430 11 Jassat W, Karim SA, Mudara C, *et al.* Clinical Severity of COVID-19 Patients Admitted to  
431 Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave. *SSRN*  
432 *Electron J* 2021. DOI:10.2139/ssrn.3996320.
- 433 12 Dagan N, Barda N, Kepten E, *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide  
434 Mass Vaccination Setting. *N Engl J Med* 2021; **384**: 1412–23.
- 435 13 Lopez Bernal J, Andrews N, Gower C, *et al.* Effectiveness of the Pfizer-BioNTech and  
436 Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and  
437 mortality in older adults in England: test negative case-control study. *BMJ* 2021; : n1088.
- 438 14 Vasileiou E, Simpson CR, Shi T, *et al.* Interim findings from first-dose mass COVID-19  
439 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective  
440 cohort study. *Lancet* 2021; **397**: 1646–57.
- 441 15 Murillo-Zamora E, Trujillo X, Huerta M, Riós-Silva M, Mendoza-Cano O. Effectiveness of  
442 BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among  
443 Healthcare Workers. *Medicina (B Aires)* 2021; **57**: 746.
- 444 16 Katz IT, Weintraub R, Bekker L-G, Brandt AM. From Vaccine Nationalism to Vaccine Equity  
445 — Finding a Path Forward. *N Engl J Med* 2021; **384**: 1281–3.
- 446 17 Worldometer. Coronavirus Cases. Worldometer. 2020; : 1–22.
- 447 18 WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly  
448 Operational Update. Geneva, Switzerland, 2022.
- 449 19 BBC News. No Title Covid-19 vaccine: First person receives Pfizer jab in UK. BBC. 2020; :  
450 Available at: <https://www.bbc.co.uk/news/uk-552273>.
- 451 20 R Core Team. R: A Language and Environment for Statistical Computing. 2020.
- 452 21 SAS Institute Inc. Cary, NC U (2016). SAS Statistical Software,. 2017.
- 453 22 Yue S, Pilon P. A comparison of the power of the t test, Mann-Kendall and bootstrap tests for  
454 trend detection / Une comparaison de la puissance des tests t de Student, de Mann-Kendall et

- 455 du bootstrap pour la détection de tendance. *Hydrol Sci J* 2004; **49**: 21–37.
- 456 23 World Data Bank. Population density (people per sq. km of land area). World Dev. Indicators.  
457 2018.
- 458 24 The World Bank. Population ages 65 and above, total. World Bank Data. 2018.
- 459 25 The World Bank. GDP (current US\$) | Data. World Bank. 2018.
- 460 26 WGI. WGI 2019 Interactive. WGI 2019. 2019; : 1.
- 461 27 Nuclear Threat Initiative (NTI), Johns Hopkins Center for Health Security (JHU). GHS Index.  
462 2020.
- 463 28 WHO. Global health services data, obesity and overweight. 2020.
- 464 29 Data OW in. COVID-19: Stringency Index, Oct 2, 2021. 2021.
- 465 30 Oxford COVID-19 Government Response Tracker. Calculation and presentation of the  
466 Stringency Index 4.0 28 April 2020. Oxford, 2020.
- 467 31 Kourentzes N, Petropoulos F. Forecasting with multivariate temporal aggregation: The case of  
468 promotional modelling. *Int J Prod Econ* 2016; **181**: 145–53.
- 469 32 Samur AA, Coskunfirat N, Saka O. Comparison of predictor approaches for longitudinal  
470 binary outcomes: application to anesthesiology data. *PeerJ* 2014; **2**. DOI:10.7717/PEERJ.648.
- 471 33 R Core Team (2020). R: A language and environment for statistical computing. R Foundation  
472 for Statistical Computing, Vienna, Austria. .
- 473 34 Zhao S, Lou J, Cao L, *et al.* Differences in the case fatality risks associated with SARS-CoV-2  
474 Delta and non-Delta variants in relation to vaccine coverage: An early ecological study in the  
475 United Kingdom. *Infect Genet Evol* 2022; **97**: 105162.
- 476 35 Altarawneh H, Chemaitelly H, Tang P, R MH, Abu-Raddad LJ. Protection afforded by prior  
477 infection against SARS-CoV-2 reinfection with the Omicron variant. *medRxiv* 2022;  
478 **https://do**. DOI:<https://doi.org/10.1101/2022.01.05.22268782>.
- 479 36 Iacobucci G. Covid-19: Fourth vaccine doses—who needs them and why? *BMJ* 2022; : o30.
- 480 37 Mullard A. How COVID vaccines are being divvied up around the world. *Nature* 2020;  
481 published online Nov 30. DOI:10.1038/d41586-020-03370-6.
- 482 38 Mukwege D, Byabene AK, Akonkwa EM, *et al.* High SARS-CoV-2 Seroprevalence in  
483 Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo. *Am J Trop Med Hyg*  
484 2021; **104**: 1526–30.
- 485 39 Ingoba LL, Ntoumi F. Seroprevalence of SARS-CoV-2 among residents of Brazzaville, the  
486 Republic of Congo. In: EDCTP Forum. Maputo, Mozambique, 2021.
- 487 40 Mandolo J, Msefula J, Henrion MYR, *et al.* SARS-CoV-2 exposure in Malawian blood  
488 donors: an analysis of seroprevalence and variant dynamics between January 2020 and July  
489 2021. *BMC Med* 2021; **19**: 303.
- 490 41 Alexandre M, Christian M, Brice MY, *et al.* Very high relative seroprevalence of anti-SARS-  
491 CoV-2 antibodies among communities in Bangui, Central African Republic. *medRxiv* 2021;  
492 **Nov 21**: Available at: <https://doi.org/10.1101/2021.11.18.2>.
- 493 42 Lau H, Khosrawipour V, Kocbach P, *et al.* The positive impact of lockdown in Wuhan on  
494 containing the COVID-19 outbreak in China. *J Travel Med* 2020; **27**.  
495 DOI:10.1093/jtm/taaa037.

- 496 43 Haider N, Osman AY, Gadzekpo A, *et al.* Lockdown measures in response to COVID-19 in  
497 nine sub-Saharan African countries. *BMJ Glob Heal* 2020; **5**: e003319.
- 498 44 Haider N, Yavlinsky A, Chang Y-M, *et al.* The Global Health Security index and Joint  
499 External Evaluation score for health preparedness are not correlated with countries' COVID-  
500 19 detection response time and mortality outcome. *Epidemiol Infect* 2020; **148**: e210.
- 501 45 Kim J, Hong K, Yum S, *et al.* Factors associated with the difference between the incidence and  
502 case-fatality ratio of coronavirus disease 2019 by country. *Sci Rep* 2021; **11**: 18938.
- 503 46 Michie S, Bullen C, Lazarus J V., *et al.* Vaccine Equity Is Crucial to End the COVID-19  
504 Pandemic — But It Won't Be Enough. 2021.
- 505 47 Haider N, Rothman-Ostrow P, Osman AY, *et al.* COVID-19—Zoonosis or Emerging  
506 Infectious Disease? *Front Public Heal* 2020; **8**: 1–8.
- 507 48 Zhang J, Zhang Y, Kang J-Y, *et al.* Potential transmission chains of variant B.1.1.7 and co-  
508 mutations of SARS-CoV-2. *Cell Discov* 2021; **7**: 44.
- 509 49 Wei C, Shan K-J, Wang W, Zhang S, Huan Q, Qian W. Evidence for a mouse origin of the  
510 SARS-CoV-2 Omicron variant. *J Genet Genomics* 2021; published online Dec.  
511 DOI:10.1016/j.jgg.2021.12.003.

512

513 **Figure legends:**

514 **Figure 1.** Top: Observed and predicted global daily reported Case-Fatality Rate (rCFR) using Simple  
515 Exponential Smoothing (SES) model. Middle: Observed and predicted daily worldwide daily  
516 cumulative rCFR using Auto-Regressive Integrated Moving Average (ARIMA) model. Bottom:  
517 Observed and predicted daily worldwide daily cumulative rCFR using Automatic Forecasting time-  
518 series model (Prophet model). The black dots indicate observed data, the blue line indicates the  
519 predictive CFR, and the shaded area indicates the 95% confidence interval of predicted CFR.

520

521 **Figure 2:** The map shows the Covid-19 vaccination rate (/100 people) and the reported Case-fatality  
522 rate (rCFR) in different countries of the world on 5 January 2022. The darker colour indicates the  
523 higher vaccination rates or higher case-fatality rates. An opposite correlation exists between COVID-  
524 19 vaccination rate and rCFR ( $r = -0.296$   $p < 0.001$ )


525

526

527

528

529 Fig 1:




530

531

532

533

534 **Fig 2**




535

536


537

### Simple Exponential Smoothing Model




Observed data 80% 95% Fitted Forecast


### Auto-Regressive Integrated Moving Average Model





Observed data 80% 95% Fitted Forecast

### Automatic Forecasting Time-series Model





Vaccination  
(doses/100 people)



Reported CFR (%)

